Literature DB >> 31443885

Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.

Mance E Buttram1, Steven P Kurtz2, Matthew S Ellis3, Theodore J Cicero3.   

Abstract

BACKGROUND: Gabapentin, a prescription medication approved for the treatment of seizures and neuralgia, is often prescribed off-label for substance use treatment, mental health problems, and pain. Emerging reports also suggest it is misused for the purpose of getting high. The present study examines substance abuse treatment provider key informants' experiences with gabapentin prescribed to clients in treatment. The focus of this exploratory study is to ascertain how gabapentin is used in these settings and the benefits and risks for clients.
METHODS: Key informants from South Florida participated in confidential, in-depth interviews (N = 12). Data analyses included descriptive and in vivo coding schemes and employed a descriptive qualitative approach.
RESULTS: All key informants recognized the benefits of prescribing gabapentin to clients in treatment for problems related to withdrawal symptoms, mental distress and pain. At the same time, half of participants described gabapentin misuse among clients and four key informants described such misuse as a first marker of relapse. Key informants also stated that more research must be done about how to use gabapentin effectively in treatment settings.
CONCLUSIONS: These findings illustrate the lack of clarity about the efficacy of administration of gabapentin in treatment settings. Additional research about how to best use gabapentin, for whom it may be beneficial, and the effect of prescribed gabapentin on addiction recovery is needed.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gabapentin; Misuse; Qualitative; Substance abuse treatment

Mesh:

Substances:

Year:  2019        PMID: 31443885      PMCID: PMC6709710          DOI: 10.1016/j.jsat.2019.07.011

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  18 in total

Review 1.  Checklists for improving rigour in qualitative research: a case of the tail wagging the dog?

Authors:  R S Barbour
Journal:  BMJ       Date:  2001-05-05

2.  The diversion of prescription drugs by health care workers in Cincinnati, Ohio.

Authors:  James A Inciardi; Hilary L Surratt; Steven P Kurtz; John J Burke
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

3.  Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky.

Authors:  Rachel V Smith; Michelle R Lofwall; Jennifer R Havens
Journal:  Am J Psychiatry       Date:  2015-05       Impact factor: 18.112

4.  A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Authors:  Barbara J Mason; Rebecca Crean; Vivian Goodell; John M Light; Susan Quello; Farhad Shadan; Kimberly Buffkins; Mark Kyle; Murali Adusumalli; Adnan Begovic; Santosh Rao
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

5.  Importance of gabapentin dose in treatment of opioid withdrawal.

Authors:  Mehrdad Salehi; Gholam Reza Kheirabadi; Mohammad Reza Maracy; Mansour Ranjkesh
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

Review 6.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

7.  Role of key informants and direct patient interviews in epidemiological studies of substance abuse.

Authors:  Theodore J Cicero; Matthew S Ellis; Alethea Paradis; Zachary Ortbal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-09       Impact factor: 2.890

8.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

9.  Gabapentin treatment for alcohol dependence: a randomized clinical trial.

Authors:  Barbara J Mason; Susan Quello; Vivian Goodell; Farhad Shadan; Mark Kyle; Adnan Begovic
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

10.  The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial.

Authors:  Mohsen Saber Moghadam; Mohammad Alavinia
Journal:  Pak J Pharm Sci       Date:  2013-09       Impact factor: 0.684

View more
  3 in total

1.  Factors Associated with Gabapentin Misuse among People Who Inject Drugs in Appalachian Kentucky.

Authors:  Mance E Buttram; Hilary L Surratt
Journal:  Subst Use Misuse       Date:  2020-09-11       Impact factor: 2.164

2.  A Qualitative Examination of Gabapentin Misuse Inside of Treatment and Recovery Settings.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

3.  Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid (Mis)users in South Florida.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Psychoactive Drugs       Date:  2020-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.